The latest type 2 diabetes medications reach blood sugar and weight goals faster

A phase III beyond trial published in 2021 confirmed that thioglin lowered blood sugar and supported weight loss

The latest analysis of the super2 and super3 trials, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, this year found that adults treated with different doses of tirzeepatide (5, 10 and 15 mg) for injection reached their blood glucose targets 4 weeks earlier than adults treated with semaglutide (1 mg) for injection, compared with degludec once a day.

"Tizeptide is unique in that it mimics two natural insulin release and appetite-suppressing hormones in one injection," said

T2D is a chronic, progressive disease in which the body is unable to make or use insulin normally, resulting in high

Telxitide is a single-molecule novel diabetes drug that mimics two hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin polypeptide (GIP), which are involved in blood sugar control and appetite suppression

The super-2 and super-3 trials compared different doses of tirzepatide (5, 10, and 15 mg) with the weekly injectable semaglutide 1 mg (which is a single hormone, GLP-1 analogue) as an add-on treatment to metformin, or long-acting insulin (iDeg) as an add-on treatment to metformin, with or without a sodium-glucose co-transporter-2 inhibitor, respectively[3

On average, the reduction rate of HbA1c in all dose tirzepatide treatment groups was higher than that in the siglutide and iDeg treatment groups, and the proportion of HbA1c was less than 7% (<53 mmol/mol), less than or equal to 6.

In this latest analysis, the researchers compared the time from the start of the study to the time they reached the glycosylated hemoglobin target and found that participants taking thioglin reached the glycosylated hemoglobin targets of less than 7% and less than 6.

The average (median) time to reach HbA1c levels below 7% is about 8 weeks for all doses of telxiptide, while cima glucoside and Edeg are both 12 weeks; Reaching 6.

Further analysis of super-2 found that participants taking tirzep peptides reached their weight loss goals significantly faster than semaglutide

"For many people, even a modest weight loss of 5 percent of their initial body weight is associated with significant clinical improvement in weight-related health problems

Mild to moderate gastrointestinal adverse events, such as nausea, vomiting, and diarrhea, occurred in participants taking thioglyptide, most commonly during dose increases and decreased

The authors acknowledge some of the study's limitations, including that the study was not specifically designed to compare glycemic control rates and weight loss rates, so these analyses should be interpreted

Table: Summary of time to reach glycosylated hemoglobin targets and weight loss thresholds